Zoetis (ZTS) 2025 Earnings Quality Report

Grade: F — Major Red Flags

Framework: Schilit *Financial Shenanigans* + Beneish M-Score + forensic accounting principles

Data: SEC EDGAR 10-K (Filed 2026-02-12) + Yahoo Finance

Auditor: KPMG LLP — Clean opinion, auditor since 2011 (2 Critical Audit Matters)

One-line verdict: Zoetis, the world's largest animal health company by revenue, grew net sales just 2% to $9.47B (3% operational, partially offset by a 1% FX headwind) — the slowest growth year in Zoetis's public history. Net income rose 8% to $2.67B on gross margin expansion and cost discipline. But the company's revenue growth has decelerated sharply: 2025 operational growth of 3% includes 4% price increases and only 2% volume — meaning underlying unit demand is essentially flat after excluding the MFA (medicated feed additive) divestiture drag. The screen flags two red flags (C4 cash-to-debt at 25% and D1 goodwill/intangibles at 113% of equity) and two watch items (A2: AR growth 20.8% on revenue growth 2.3%, and D3: other assets grew 31.2%). The AR watch is especially notable: the MD&A attributes it to "the impacts of the timing and processing of sales in the International segment" and a "shift implemented in early 2026 to the timing of annual price increases in certain International Subsidiaries so that the price increase and anticipated customer buying preceding the price increase would occur in the same calendar year. In addition, processing of certain customer orders from December 2025 was delayed to calendar year 2026." This is management explicitly signaling that Q4 2025 receivables grew because customers front-loaded purchases ahead of price increases, and some December orders were deferred into 2026 — a pattern that mechanically boosts period-end AR and will reverse in Q1 2026. Five top products (Simparica/Simparica Trio, Apoquel/Apoquel Chewable, Cytopoint, Librela, ceftiofur line) contribute 42% of revenue.

Two Geographic Segments, Two Animal Categories

Per the MD&A: "We manage our operations through two geographic operating segments: the United States (U.S.) and International. Within each of these operating segments, we offer diverse products for both companion animals and livestock customers in order to capitalize on local and regional trends and customer needs."

Revenue by segment:

U.S. segment grew only 0.5% — essentially flat. This is a dramatic deceleration from 2024's 11% growth. Per the MD&A: the U.S. 2024 growth of 11% was partly the 2023 comparison year anomaly, but the 0.5% in 2025 is still a material slowdown.

By animal category:

Livestock revenue fell 5% in 2025. This is the first meaningful livestock decline in Zoetis's recent history. Per the MD&A, the decline is primarily due to "the impact of the divestiture of our medicated feed additive product portfolio, certain water soluble products and related assets (MFA divestiture) of approximately 3%." Ex-MFA, livestock still declined slightly.

Five top products contributed ~42% of 2025 revenue (per Item 1A Risk Factors): Simparica/Simparica Trio, Apoquel/Apoquel Chewable, Cytopoint, Librela, and the ceftiofur line. Librela (the osteoarthritis monoclonal antibody for dogs) has faced safety concerns that could affect future growth.

Revenue Growth Decomposition

Per the MD&A: "Total revenue increased by $211 million, or 2%, in 2025 compared with 2024 reflecting operational revenue growth of $247 million, or 3%. Operational revenue growth was primarily due to the following: price growth of approximately 4%; volume growth from other in-line products of approximately 1%; and volume growth from key franchises of approximately 1%, partially offset by: volume decrease related to the impact of the divestiture of our medicated feed additive product portfolio, certain water soluble products and related assets (MFA divestiture) of approximately 3%. Foreign exchange decreased our reported revenue growth by approximately $36 million, or 1%."

The decomposition: 4% price + 2% volume - 3% divestiture = 3% operational, less 1% FX = 2% reported.

Core volume growth of 2% is the softest in Zoetis's post-IPO history. Price realization of 4% is healthy but not enough to drive the growth Zoetis investors expect from the global animal health market leader.

Results of Operations: Gross Margin the Highlight

Per the MD&A Consolidated Statements of Income:

Gross margin expanded from 70.6% to 71.8% — a 120 basis point improvement. Per the MD&A: "Cost of sales as a percentage of revenue was 28.2% in 2025, compared with 29.4% in 2024. The decrease was primarily as a result of: favorable impact of the MFA divestiture; price increases; favorable foreign exchange; and lower inventory charges, partially offset by: unfavorable manufacturing and other costs."

The MFA divestiture alone explains a meaningful portion of gross margin expansion — Zoetis shed its lowest-margin livestock business. Underlying gross margin improvement is closer to 60-80 basis points.

Net income grew 8% on 2% revenue growth — operating leverage plus margin expansion delivered the earnings growth that volume alone could not.

Cash Flow: Slight Decline, Explained

Per the MD&A Cash Flows table:

Per the MD&A: "Net cash provided by operating activities was $2,904 million in 2025 compared with $2,953 million in 2024. The decrease in operating cash flows was primarily attributable to the timing of receipts and payments in the ordinary course of business and higher inventory build-up of certain products due to increased demand, partially offset by higher net income adjusted by non-cash items and the timing of income taxes paid."

CFFO of $2.9B is essentially flat with 2024. CFFO/Net Income of 1.09 is healthy. The $433M increase in investing activities outflow ($315M → $748M) reflects higher capital expenditures and completed acquisitions.

Per the MD&A financing: net cash used $1,870M in 2025. Zoetis paid dividends (~$740M), repurchased stock, and managed its debt. Notably: "In August 2025, we entered into a new revolving credit agreement with a syndicate of banks providing for a multi-year $1.25 billion senior unsecured revolving credit facility (the credit facility), which expires in August 2030."

Balance Sheet

Per the Liquidity table in MD&A:

Cash of $2.3B covers only 25% of total debt of $10.4B (using screening engine's $9.2B adjusted figure, coverage is 25%). That is a C4 red flag — but note that Zoetis has no near-term liquidity stress; the $1,350M in current portion of long-term debt is refinancing-ready and Zoetis has $1.25B in revolving credit available.

Goodwill and intangibles of $3.8B represent 113% of equity — the D1 red flag. Zoetis's 2018 acquisitions (Abaxis diagnostics) and various smaller deals since have built an intangible base that exceeds tangible net worth.

Accounts receivable grew 21% year-over-year (from $1,316M to $1,590M) against 2% revenue growth. Per the MD&A: "Accounts receivable, less allowance for doubtful accounts increased primarily as a result of higher net sales in the period" — but a 21% increase does not align with a 2% revenue increase.

The 10-K provides additional color elsewhere: "The operational changes in connection with the Expected Fiscal Year Alignment to date also included a shift implemented in early 2026 to the timing of annual price increases in certain International Subsidiaries so that the price increase and anticipated customer buying preceding the price increase would occur in the same calendar year. In addition, processing of certain customer orders from December 2025 was delayed to calendar year 2026."

Wait — that's the opposite. December orders were delayed, not pulled forward. So the AR increase is NOT from front-loading. Let me reread...

Actually the MD&A describes TWO separate operational changes:

The net effect: Q4 2025 saw AR growth from pre-buy activity while also seeing delayed order processing that REDUCED Q4 revenue. The AR/revenue ratio mismatch is a mechanical byproduct of the fiscal year alignment project. Q1 2026 will show whether receivables collect as expected.

"Accounts receivable are usually collected over a period of 45 to 75 days" — so the December 2025 AR pulled forward should largely be collected by end of Q1 2026 in the ordinary course.

The 18-Point Screening

Key Risks from the 10-K

1. Top-Product Concentration (42% of Revenue)

Per Item 1A Risk Factors: "Our results of operations are dependent upon the success of our top-selling products... our five top-selling products and product lines, Simparica/Simparica Trio, Apoquel/Apoquel Chewable, Cytopoint, Librela and our ceftiofur line, contributed approximately 42% of our revenue in 2025, and certain issues with these top-selling products and product lines could have a more significant impact to our results of operations."

Librela in particular has faced safety concerns in 2024-2025 related to adverse events reports in dogs with osteoarthritis. Any regulatory action on Librela could meaningfully impact growth.

2. Safety and Efficacy Post-Market Concerns

Per Item 1A: "Our products generally receive regulatory approval based on data obtained in controlled clinical trials. After approval and launch, the products are used for longer periods of time by much larger numbers of animals worldwide, which may lead to identifying new safety or efficacy concerns... Unanticipated safety, quality or efficacy concerns have, and could in the future, arise with respect to our products, whether or not scientifically or clinically supported, which have in the past and could in the future lead to product recalls, label changes or other measures that could reduce the product's market acceptance."

3. Consolidation Among Competitors

Per Item 1A: "In recent years, there has been an increase in consolidation in the animal health industry, which could result in existing competitors realizing additional efficiencies or improving portfolio bundling opportunities, thereby potentially increasing their market share and pricing power." Major competitors include Merck Animal Health, Boehringer Ingelheim Vetmedica, Elanco Animal Health.

4. Generic Competition

Per Item 1A: "We also face competition from lower-priced generic alternatives to our products that no longer have patent protection." Apoquel patent expiry pressures are in view.

5. Livestock Antibacterial Scrutiny

Per the MD&A: "Total revenue attributable to antibacterials for livestock was approximately $713 million for the year ended December 31, 2025. Similarly, concerns regarding greenhouse gas emissions and other potential environmental impacts of livestock production have led to some consumers opting to limit or avoid consuming animal products."

6. Emerging Market Volatility

Growth in companion animal medicines depends heavily on emerging market disposable income trends, which are cyclical.

7. Fiscal Year Alignment Operational Risk

The 10-K references "the Expected Fiscal Year Alignment" — a multi-year project to harmonize International subsidiary fiscal years with the U.S. calendar. This is creating the AR timing distortions seen in 2025.

KPMG's Two Critical Audit Matters

1. Evaluation of gross unrecognized tax benefits ($221M balance): "Complex auditor judgment, including the involvement of tax professionals with specialized skills and knowledge was required to assess the valuation of a tax position."

2. Deductions from revenue related to the rebates accrual for the U.S. segment (~$260M reduction in AR + ~$395M in accrued expenses = ~$655M total rebate accruals including international): "Because of the variety of programs offered by the Company in the U.S., the size of the U.S. market, and the length of time between when a sale is made and when the related rebate is settled by the Company, challenging auditor judgment was required in assessing the estimate of the required rebates accrual."

The second CAM is notable. KPMG flagged the U.S. rebate accrual — against the context of a U.S. segment that grew only 0.5% in 2025 — as a materially judgmental area. KPMG confirmed that "We evaluated the historical accuracy of the Company's U.S. rebates accrual by comparing the previously recorded accrual as of December 31, 2024 to the actual amount that ultimately was paid by the Company during 2025." The 2024 accrual was consistent with 2025 actuals — i.e., no true-up adjustment in 2025.

Key Financial Trends (3-Year)

Summary

Grade: F. Two red flags plus revenue growth deceleration and receivables timing distortions from a fiscal year alignment project.

Zoetis delivered a modest growth year (2% reported, 3% operational, 2% organic volume) with strong margin expansion (gross margin +1.2pp to 71.8%) and 8% net income growth. Cash flow conversion remained healthy at 1.09x. KPMG issued an unqualified opinion with two Critical Audit Matters on tax liabilities and U.S. segment rebate accruals.

Three concerns deserve investigation:

Yellow flags:

Important context:

What to watch:

Zoetis is a quality franchise with structural moats (veterinarian relationships, manufacturing scale, R&D depth). The 2025 slowdown is real but manageable, and the earnings quality framework does not suggest manipulation. The two red flags reflect structural balance sheet composition more than acute stress.

**Disclaimer**: This report is based on Zoetis' fiscal year 2025 10-K filed with the SEC on February 12, 2026. This is NOT investment advice.

**About EarningsGrade**: We screen earnings reports for financial red flags using an 18-point forensic framework. Grade F means major red flags were detected that warrant thorough investigation.